Polynucleotide (Rejuran / PDRN) Skin Boosters in Seoul: A Dermatologist's 2026 Evidence Guide for International Patients

What polynucleotide skin boosters actually are

If you have searched for "Korean glass skin treatment" in the past two years, you have almost certainly seen the word Rejuran alongside it. Rejuran is the brand name; the underlying technology is polynucleotide (PN) — also called polydeoxyribonucleotide (PDRN) — a regenerative injectable derived from purified salmon DNA fragments. Salmon is used because its DNA shares high sequence homology with human DNA, while being free from the viral risks of mammalian-sourced material.

The clinical category is "skin booster," not "filler." This distinction matters because the goals are completely different:

• HA fillers (Juvéderm, Restylane) physically add volume at injection time. Effect is immediate and dose-dependent.
• Skin boosters (Rejuran, Skinvive, Profhilo) deposit very small amounts of bioactive material superficially. They do not add visible volume — they signal the dermis to repair itself.
• Biostimulators (Sculptra, Radiesse) trigger collagen rebuilding deep in the dermis. Goal is volume restoration through structural collagen, not surface quality.

Rejuran sits in the skin-booster category, which means patients comparing it to a filler — or to Sculptra — are mostly comparing different goals. The honest question is not "which is better" but "which goal matches what your skin needs."

What polynucleotide actually does in the skin

The mechanism is well-studied at this point. A 2017 systematic review in Current Pharmaceutical Design documented the full pharmacology: PDRN activates adenosine A2A receptors on fibroblasts, increases VEGF (vascular endothelial growth factor) release, accelerates capillary formation, and stimulates type I collagen synthesis in damaged skin (Squadrito et al., PMID 29028075). Most of this evidence comes from wound healing and tissue regeneration medicine — burn treatment, diabetic ulcers, ischemic flap survival — where PDRN has decades of clinical use that predates its aesthetic application.

The aesthetic-specific evidence is younger and thinner, but it is accumulating. A 2020 split-face study in Journal of Cosmetic Dermatology by Kim and colleagues (Korean cohort, N=20) measured 12-week outcomes after Rejuran injections and documented improvement in skin elasticity and increased dermal thickness on the treated side versus untreated (Kim et al., PMID 31702128). A 2020 randomized split-face study by Jeong and colleagues in the same journal compared polynucleotide to polycaprolactone fillers for crow's-feet correction and found comparable efficacy with different recovery profiles (PMID 31680395).

A 2026 review in Journal of Cosmetic Dermatology on regenerative aesthetics (Barbosa AP, PMID 41572953) places polynucleotides in the broader regenerative-medicine framework alongside Sculptra, exosomes, and growth-factor protocols — useful context for patients trying to understand where Rejuran fits in the 2026 skin-quality landscape. And a 2026 multispecialty systematic review of under-eye treatments (Beer et al., Dermatologic Surgery, PMID 41615388) specifically addresses polynucleotide use for periorbital indications, a high-demand Rejuran use case.

Honest framing of the evidence base: the PDRN mechanism is well-established. The aesthetic-specific RCT evidence is mostly Korean, mostly small (N<50), mostly split-face design, and mostly open-label rather than blinded. This is a real limitation. The clinical experience base — particularly in Seoul, where Rejuran originated and where the protocol was refined — is much larger than the published literature, which is the inverse of the situation with Sculptra or Ultherapy. We treat that evidence asymmetry transparently in consultation rather than overclaim.

How Rejuran compares with the other skin boosters available in Seoul

Seoul has the densest skin-booster ecosystem in the world, which is part of why "K-beauty glass skin" search interest funnels here. The three injectable categories patients ask about most often:

1. Rejuran (polynucleotide / PDRN) — Korean, salmon-derived. Mechanism: A2A-receptor activation + fibroblast recruitment + VEGF + collagen synthesis. Best for: damaged skin texture, fine lines, post-acne quality, under-eye thinning, post-laser recovery acceleration. Protocol: 3–4 sessions, 2–4 weeks apart. Honest evidence rating: mechanism strong, aesthetic RCTs growing but thin.

2. Skinvive / Juvéderm Volite (hyaluronic acid skin booster) — FDA-approved June 2023 as the first HA product approved for skin-quality (not filler) indications. Mechanism: stabilized HA microdroplets that improve hydration, smoothness, and elasticity. The pivotal U.S. trial (N=330, 2:1 randomization vs. no-treatment) showed statistically significant Clinician Global Assessment improvement at 6 months — the strongest regulatory evidence in this category. A 2017 study by Niforos and colleagues in Dermatologic Surgery documented 6–9 month duration with measurable improvements in skin moisture and elasticity (PMID 29033598). Best for: patients who want one session (lasts 6–9 months) and the strongest published trial data.

3. Profhilo — NAHYCO-technology hyaluronic acid. Stabilized without chemical cross-linkers using thermal binding of high- and low-molecular-weight HA chains. Delivered via the "BAP" technique (5 injection points per side). Avcil and Akici (2021, Journal of Cosmetic Dermatology, PMID 33788388) used Cutometer measurements to document 10–30% improvement in skin elasticity parameters (R2 and R5) two months post-treatment. Profhilo is CE-marked but not FDA-approved in the U.S.; widely used in Asia and Europe. Best for: patients who want a quick 2-session course (4 weeks apart) and well-tolerated downtime.

None of these are interchangeable. The right starting point depends on whether your concern is hydration (Skinvive), elasticity (Profhilo), or active regeneration plus texture (Rejuran). Many international patients in Seoul receive a combination — for example, Rejuran for under-eye thinning plus Skinvive for cheek hydration in the same trip, with the dermatologist sequencing injections so the depth and indication of each layer is appropriate.

What an authentic Rejuran protocol at Delight looks like

Delight Dermatology Clinic is a Rejuran Club VIP certified center — a Pharma Research Bio (the original Korean manufacturer) certification awarded only to clinics with documented clinical experience and verified authentic product sourcing. The certification matters because Rejuran's popularity has produced a parallel market of refilled or generic PDRN injectables in some Seoul clinics, where the salmon-DNA source, purification standard, and lot traceability cannot be verified. Club VIP status confirms direct manufacturer sourcing and quarterly inventory audit.

The standard protocol is straightforward:

• 3–4 sessions, 2–4 weeks apart. Most patients see meaningful change starting at session 2; full effect typically at 4–6 weeks after the final session.
• Product selection. Rejuran Healer (most common — global texture and elasticity), Rejuran HB+ (for hydration-focused indication), Rejuran I (for periorbital — under-eye area, lower concentration and finer needle).
• Injection depth. Multiple superficial intradermal microinjections across the treatment field. Not a deep filler-style placement.
• Anesthesia. Topical numbing cream 30 minutes before the procedure is standard. Some patients add 1% lidocaine if the practitioner uses a higher-volume technique.
• Downtime. Tiny wheals at injection sites that resolve within 12–24 hours. Mild pinpoint bruising in roughly 15–25% of patients (depending on technique and patient anticoagulant status). Most patients are social-acceptable the same day.

Results are gradual by design. The mechanism is fibroblast signaling and collagen synthesis — biological processes that need weeks to express visibly. Patients expecting an immediate "filled-out" look are matched to a different product category at consultation rather than pushed onto Rejuran.

Candidate selection — who Rejuran is and is not for

Good candidates are typically:

• Patients whose primary concern is skin quality (texture, fine lines, dehydration, post-acne dullness, periorbital thinning) rather than volume loss.
• Patients willing to invest 6–8 weeks for a 3-session course rather than expecting a single-visit transformation.
• Patients who have completed the volume-replacement phase (filler or biostimulator) and want to move to a quality-focused maintenance layer.
• Patients in post-laser recovery — Rejuran is well-documented as an accelerator for downtime resolution after ablative or fractional laser treatments.

Rejuran is not a good fit for: patients with active midface volume loss (Sculptra or HA filler is the correct category), patients who want a one-session transformation (Skinvive or Profhilo are better matches), or patients with bleeding disorders or active anticoagulant therapy without physician clearance (increased bruising risk from multi-point superficial injection).

Honest note on cost: Rejuran is positioned in the "skin quality" rather than "volume" tier in our pricing, and the 3-session course total cost is typically lower than a single Sculptra series but higher than a single Skinvive treatment. The right framing is per-month or per-year cost-of-results rather than per-session quote.

FAQ

Is "K-beauty glass skin" actually achievable with Rejuran? "Glass skin" is a marketing aesthetic with no single procedure that produces it. The reality is a stacked approach: sun protection + barrier-supportive skincare + appropriate professional treatments. Rejuran is one of the higher-evidence components for the dermal-quality layer of that stack, but treating Rejuran as a standalone solution overpromises what any single injectable can do.

How does this compare to home skincare? Home skincare works at the epidermis. Rejuran works in the dermis. They are complementary layers, not alternatives. A patient with strong home skincare habits is typically a better Rejuran candidate because the surface is already optimized — the injection has more room to add value.

Are exosomes a better newer option? Exosome-based skin treatments are aggressively marketed in Seoul but their evidence base in 2026 is still mostly preclinical (cell culture + animal studies). No exosome product is FDA-approved for cosmetic use, and the FDA has issued public warnings about unapproved exosome products. Early clinical reports are promising but insufficient to recommend exosomes over polynucleotides as a first-line skin booster choice today. We discuss this transparently rather than upselling.

What about combining Rejuran with Sculptra or HA filler in one trip? Yes — many international patients do exactly this. The dermatologist plans depth and sequence (deeper layers first, then quality layer last), with appropriate intervals when the same anatomical zone is being treated. We do not stack multiple injectables in the same anatomical depth in a single session because that is where complication risk concentrates.

Is Rejuran available outside Korea? Yes, in many markets. But the Korean clinical experience density, the Club VIP certified clinic network, and the authentic product sourcing audit are all materially stronger in Seoul than in most other markets. Patients flying in specifically for Rejuran are typically doing so for the practitioner experience and supply integrity, not for the product itself, which is increasingly available globally.

Reviewed by

This article was reviewed by Dr. SangYoul Yun, Board-Certified Dermatologist · AAD International Fellow (IFAAD) · ASLMS member · Rejuran Club VIP-certified. Last reviewed: 2026-05-14. Citations are anchored in PubMed and verified at publication.

Sources

1. Squadrito F et al. Pharmacological Activity and Clinical Use of PDRN. Current Pharmaceutical Design. 2017. PMID 29028075
2. Kim BJ et al. Korean Rejuran split-face skin elasticity study. Journal of Cosmetic Dermatology. 2020. PMID 31702128
3. Jeong GJ et al. Polynucleotide vs polycaprolactone for crow's feet. Journal of Cosmetic Dermatology. 2020;19(7):1593-1599. PMID 31680395
4. Niforos F et al. VYC-12 (Skinvive) skin-quality study. Dermatologic Surgery. 2017. PMID 29033598
5. Avcil M, Akici M. Profhilo elasticity outcomes via Cutometer. Journal of Cosmetic Dermatology. 2021. PMID 33788388
6. Barbosa AP. Regeneration in Aesthetic Medicine: Mechanisms, Evidence, and Clinical Boundaries. Journal of Cosmetic Dermatology. 2026 Jan. PMID 41572953
7. Beer J, Boghosian T, Sherif R et al. What's New With Under Eye Treatment: A Multispecialty Systematic Review. Dermatologic Surgery. 2026 Feb. PMID 41615388